07:43 AM EDT, 06/24/2025 (MT Newswires) -- iBio (IBIO) said Tuesday that an engineered amylin receptor agonist antibody reduced acute food intake in a mouse model of obesity by 60% in data from a preclinical study.

The effect on food intake was monitored over various time points in a side-by-side study with the amylin agonist iBio discovered and a DACRA peptide, the company said.

The study was part of a partnership with AstralBio, the company said.

Shares of the company rose more than 45% in recent premarket activity.

Price: 1.04, Change: +0.3276, Percent Change: +45.99